Get ready to unlock the secrets behind Carl Zeiss Meditec’s stellar Q1-2022/23 financial results!
Â
Join Markus Weber, CEO, and Justus Felix Wehmer, CFO, as they take you through the numbers and share their insights. Watch the Q1-2022/23 financial presentation by CEO Markus Weber and CFO Justus Felix Wehmer and get the latest updates on the company’s revenue growth, operating results, and future outlook.
Â
Carl Zeiss shows strong growth, with revenue up by 14.6% (adjusted for currency effects: +12.1%). Despite the challenging environment, the team has pulled out all the stops to reduce customer delivery times while continuing to invest in future growth.
Â
The Ophthalmology and Microsurgery strategic business units contributed to growth, with solid growth rates reported in all regions. However, there was a weaker operating result than the prior year due to higher operating costs and a weaker product mix. But the outlook for the further course of business in 2022/23 remains positive, with the company expecting further market growth and revenue growth to be at least as strong as the market.
Â
Carl Zeiss Meditec AG will continue to invest in sales, marketing, and research and development to launch new products and innovations. We can’t wait to see what the future holds for this innovative company!
Â
As the CEO himself says, “Our team is pulling out all the stops to reduce delivery time for our customers. At the same time, we are also continuously investing in our future growth.”
Â
You want to attend this presentation, available at seat11a!
February 21, 2023
seat11a – Publicly Listed Companies: Elevator Pitch, Deep-Dive, Financial Results, and ESGÂ
Reviews for Carl Zeiss Meditec AG Financial Results Q1 2022 / 23 | Unlocking the Stellar Performance with CEO and CFO